Cargando…
A framework for assessing clinical trial site readiness
Clinical trial processes are unnecessarily inefficient and costly, slowing the translation of medical discoveries into treatments for people living with disease. To reduce redundancies and inefficiencies, a group of clinical trial experts developed a framework for clinical trial site readiness based...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346039/ https://www.ncbi.nlm.nih.gov/pubmed/37456265 http://dx.doi.org/10.1017/cts.2023.541 |
_version_ | 1785073224994783232 |
---|---|
author | Buse, John B. Austin, Christopher P. Johnston, S. Claiborne Lewis-Hall, Freda March, Andrew N. Shore, Carolyn K. Tenaerts, Pamela Rutter, Joni L. |
author_facet | Buse, John B. Austin, Christopher P. Johnston, S. Claiborne Lewis-Hall, Freda March, Andrew N. Shore, Carolyn K. Tenaerts, Pamela Rutter, Joni L. |
author_sort | Buse, John B. |
collection | PubMed |
description | Clinical trial processes are unnecessarily inefficient and costly, slowing the translation of medical discoveries into treatments for people living with disease. To reduce redundancies and inefficiencies, a group of clinical trial experts developed a framework for clinical trial site readiness based on existing trial site qualifications from sponsors. The site readiness practices are encompassed within six domains: research team, infrastructure, study management, data collection and management, quality oversight, and ethics and safety. Implementation of this framework for clinical trial sites would reduce inefficiencies in trial conduct and help prepare new sites to enter the clinical trials enterprise, with the potential to improve the reach of clinical trials to underserved communities. Moreover, the framework holds benefits for trial sponsors, contract research organizations, trade associations, trial participants, and the public. For novice sites considering future trials, we provide a framework for site preparation and the engagement of stakeholders. For experienced sites, the framework can be used to assess current practices and inform and engage sponsors, staff, and participants. Details in the supplementary materials provide easy access to key regulatory documents and resources. Invited perspective articles provide greater depth from a systems, DEIA (diversity, equity, inclusion, and accessibility) and decentralized trials perspective. |
format | Online Article Text |
id | pubmed-10346039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103460392023-07-15 A framework for assessing clinical trial site readiness Buse, John B. Austin, Christopher P. Johnston, S. Claiborne Lewis-Hall, Freda March, Andrew N. Shore, Carolyn K. Tenaerts, Pamela Rutter, Joni L. J Clin Transl Sci Special Communications Clinical trial processes are unnecessarily inefficient and costly, slowing the translation of medical discoveries into treatments for people living with disease. To reduce redundancies and inefficiencies, a group of clinical trial experts developed a framework for clinical trial site readiness based on existing trial site qualifications from sponsors. The site readiness practices are encompassed within six domains: research team, infrastructure, study management, data collection and management, quality oversight, and ethics and safety. Implementation of this framework for clinical trial sites would reduce inefficiencies in trial conduct and help prepare new sites to enter the clinical trials enterprise, with the potential to improve the reach of clinical trials to underserved communities. Moreover, the framework holds benefits for trial sponsors, contract research organizations, trade associations, trial participants, and the public. For novice sites considering future trials, we provide a framework for site preparation and the engagement of stakeholders. For experienced sites, the framework can be used to assess current practices and inform and engage sponsors, staff, and participants. Details in the supplementary materials provide easy access to key regulatory documents and resources. Invited perspective articles provide greater depth from a systems, DEIA (diversity, equity, inclusion, and accessibility) and decentralized trials perspective. Cambridge University Press 2023-05-08 /pmc/articles/PMC10346039/ /pubmed/37456265 http://dx.doi.org/10.1017/cts.2023.541 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
spellingShingle | Special Communications Buse, John B. Austin, Christopher P. Johnston, S. Claiborne Lewis-Hall, Freda March, Andrew N. Shore, Carolyn K. Tenaerts, Pamela Rutter, Joni L. A framework for assessing clinical trial site readiness |
title | A framework for assessing clinical trial site readiness |
title_full | A framework for assessing clinical trial site readiness |
title_fullStr | A framework for assessing clinical trial site readiness |
title_full_unstemmed | A framework for assessing clinical trial site readiness |
title_short | A framework for assessing clinical trial site readiness |
title_sort | framework for assessing clinical trial site readiness |
topic | Special Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346039/ https://www.ncbi.nlm.nih.gov/pubmed/37456265 http://dx.doi.org/10.1017/cts.2023.541 |
work_keys_str_mv | AT busejohnb aframeworkforassessingclinicaltrialsitereadiness AT austinchristopherp aframeworkforassessingclinicaltrialsitereadiness AT johnstonsclaiborne aframeworkforassessingclinicaltrialsitereadiness AT lewishallfreda aframeworkforassessingclinicaltrialsitereadiness AT marchandrewn aframeworkforassessingclinicaltrialsitereadiness AT shorecarolynk aframeworkforassessingclinicaltrialsitereadiness AT tenaertspamela aframeworkforassessingclinicaltrialsitereadiness AT rutterjonil aframeworkforassessingclinicaltrialsitereadiness AT busejohnb frameworkforassessingclinicaltrialsitereadiness AT austinchristopherp frameworkforassessingclinicaltrialsitereadiness AT johnstonsclaiborne frameworkforassessingclinicaltrialsitereadiness AT lewishallfreda frameworkforassessingclinicaltrialsitereadiness AT marchandrewn frameworkforassessingclinicaltrialsitereadiness AT shorecarolynk frameworkforassessingclinicaltrialsitereadiness AT tenaertspamela frameworkforassessingclinicaltrialsitereadiness AT rutterjonil frameworkforassessingclinicaltrialsitereadiness |